Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Ficek, Joanna ^a   Zygmunt, Magdalena ^a   Piechota, Marcin ^a   Hoinkis, Dzesika ^a   Rodriguez Parkitna, Jan ^a   Przewlocki, Ryszard ^a   Korostynski, Michal ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Gene expression profile; Hippocampus; NMDA antagonists; Striatum

Indexed keywords

ALCOHOL; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; FLUOXETINE; GLUCOSE TRANSPORTER 1; INSULIN; INTERLEUKIN 6; KETAMINE; MEMANTINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OPIATE; PER1 PROTEIN; PHENCYCLIDINE; PSYCHOSTIMULANT AGENT; SERUM AND GLUCOCORTICOID REGULATED KINASE 1; TIANEPTINE; ANESTHETIC AGENT; LIGAND; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TRANSCRIPTOME;

ACUTE DRUG ADMINISTRATION; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARRDC2 GENE; ARTICLE; C57BL 6 MOUSE; COMPARATIVE STUDY; CONTROLLED STUDY; CORPUS STRIATUM; CSRNP1 GENE; DBP GENE; DUSP1 GENE; FGF11 GENE; FKBP5 GENE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; GJB6 GENE; HIF3A GENE; HIPPOCAMPUS; MALE; MAP3K6 GENE; MAT2A GENE; MICROARRAY ANALYSIS; MOUSE; NEXT GENERATION SEQUENCING; NFKBIA GENE; NONHUMAN; PER1 GENE; PLEKHF1 GENE; PLIN4 GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RGCC GENE; SCRT2 GENE; SGK1 GENE; SIGNAL TRANSDUCTION; SLC2A1 GENE; TSC22D3 GENE; WHOLE GENOME MICROARRAY PROFILING; ANIMAL; BIOLOGY; CLUSTER ANALYSIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; METABOLISM; PROCEDURES; REPRODUCIBILITY;

ANESTHETICS, DISSOCIATIVE; ANIMALS; ANTIDEPRESSIVE AGENTS; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; CORPUS STRIATUM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIPPOCAMPUS; KETAMINE; LIGANDS; MALE; MICE; RECEPTORS, N-METHYL-D-ASPARTATE; REPRODUCIBILITY OF RESULTS; TRANSCRIPTOME;

EID: 84969168170     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-016-2713-3     Document Type: Article

References (47)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47(4):351-4.
2. Aan Het Rot M, Zarate Jr CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry. 2012;72(7):537-47.
3. Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther. 2013;19(6):370-80.
4. Tsukada H, Harada N, Nishiyama S, Ohba H, Sato K, Fukumoto D, Kakiuchi T. Ketamine decreased striatal [(11)C]raclopride binding with no alterations in static dopamine concentrations in the striatal extracellular fluid in the monkey brain: multiparametric PET studies combined with microdialysis analysis. Synapse. 2000;37(2):95-103.
5. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry. 2002;7(8):837-44.
6. Salat K, Siwek A, Starowicz G, Librowski T, Nowak G, Drabik U, Gajdosz R, Popik P. Antidepressant-like effects of ketamine, norketamine and dehydronorketamine in forced swim test: role of activity at NMDA receptor. Neuropharmacology. 2015;99:301-7.
7. Hillhouse TM, Porter JH. Ketamine, but not MK-801, produces antidepressant-like effects in rats responding on a differential-reinforcement-of-low-rate operant schedule. Behav Pharmacol. 2014;25(1):80-91.
8. Hillhouse TM, Porter JH, Negus SS. Comparison of antidepressant-like and abuse-related effects of phencyclidine in rats. Drug Dev Res. 2014;75(8):479-88.
9. Zarate Jr CA, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163(1):153-5.
10. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A. 2014;111(23):8649-54.
11. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010;329(5994):959-64.
12. Chatterjee M, Verma R, Ganguly S, Palit G. Neurochemical and molecular characterization of ketamine-induced experimental psychosis model in mice. Neuropharmacology. 2012;63(6):1161-71.
13. Korostynski M, Piechota M, Dzbek J, Mlynarski W, Szklarczyk K, Ziolkowska B, Przewlocki R. Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs. BMC Genomics. 2013;14:606.
14. Zarate Jr CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856-64.
15. Feder A, Parides MK, Murrough JW, Perez AM, Morgan JE, Saxena S, Kirkwood K, Aan Het Rot M, Lapidus KA, Wan LB. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry. 2014;71(6):681-8.
16. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry. 2014;4:e469.
17. De Luca MT, Meringolo M, Spagnolo PA, Badiani A. The role of setting for ketamine abuse: clinical and preclinical evidence. Rev Neurosci. 2012;23(5-6):769-80.
18. Liu F, Paule MG, Ali S, Wang C. Ketamine-induced neurotoxicity and changes in gene expression in the developing rat brain. Curr Neuropharmacol. 2011;9(1):256-61.
19. Marvanova M, Lakso M, Wong G. Identification of genes regulated by memantine and MK-801 in adult rat brain by cDNA microarray analysis. Neuropsychopharmacology. 2004;29(6):1070-9.
20. Nadler JJ, Zou F, Huang H, Moy SS, Lauder J, Crawley JN, Threadgill DW, Wright FA, Magnuson TR Large-scale gene expression differences across brain regions and inbred strains correlate with a behavioral phenotype. Genetics. 2006;174(3):1229-36.
21. Scatton B, Simon H, Le Moal M, Bischoff S. Origin of dopaminergic innervation of the rat hippocampal formation. Neurosci Lett. 1980;18(2):125-31.
22. Ouchi Y, Kubota Y, Kuramasu A, Watanabe T, Ito C. Gene expression profiling in whole cerebral cortices of phencyclidine- or methamphetamine-treated rats. Brain Res Mol Brain Res. 2005;140(1-2):142-9.
23. Tan S, Rudd JA, Yew DT. Gene expression changes in GABA(A) receptors and cognition following chronic ketamine administration in mice. PLoS One. 2011;6(6):e21328.
24. Fukunaga K, Miyamoto E. Role of MAP kinase in neurons. Mol Neurobiol. 1998;16(1):79-95.
25. Slezak M, Korostynski M, Gieryk A, Golda S, Dzbek J, Piechota M, Wlazlo E, Bilecki W, Przewlocki R Astrocytes are a neural target of morphine action via glucocorticoid receptor-dependent signaling. Glia. 2013;61(4):623-35.
26. Lang F, Strutz-Seebohm N, Seebohm G, Lang UE. Significance of SGK1 in the regulation of neuronal function. J Physiol. 2010;588(Pt 18):3349-54.
27. Anacker C, Cattaneo A, Musaelyan K, Zunszain PA, Horowitz M, Molteni R, Luoni A, Calabrese F, Tansey K, Gennarelli M. Role for the kinase SGK1 in stress, depression, and glucocorticoid effects on hippocampal neurogenesis. Proc Natl Acad Sci U S A. 2013;110(21):8708-13.
28. Duric V, Banasr M, Licznerski P, Schmidt HD, Stockmeier CA, Simen AA, Newton SS, Duman RS. A negative regulator of MAP kinase causes depressive behavior. Nat Med. 2010;16(11):1328-32.
29. Bob P, Raboch J, Maes M, Susta M, Pavlat J, Jasova D, Vevera J, Uhrova J, Benakova H, Zima T. Depression, traumatic stress and interleukin-6. J Affect Disord. 2010;120(1-3):231-4.
30. Kleinridders A, Cai W, Cappellucci L, Ghazarian A, Collins WR, Vienberg SG, Pothos EN, Kahn CR. Insulin resistance in brain alters dopamine turnover and causes behavioral disorders. Proc Natl Acad Sci U S A. 2015;112(11):3463-8.
31. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91-5.
32. Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariante CM. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry. 2013;18(12):1236-41.
33. Cao R, Li A, Cho HY, Lee B, Obrietan K. Mammalian target of rapamycin signaling modulates photic entrainment of the suprachiasmatic circadian clock. J Neurosci. 2010;30(18):6302-14.
34. Binder EB, Salyakina D, Lichtner P, Wochnik GM, Ising M, Putz B, Papiol S, Seaman S, Lucae S, Kohli MA, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36(12):1319-25.
35. Binder EB. The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders. Psychoneuroendocrinology. 2009;34 Suppl 1:S186-95.
36. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry. 2008;64(2):89-97.
37. Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, McLoughlin DM, Meaney J, O'Keane V, Connor TJ. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl Psychiatry. 2012;2:e88.
38. Piechota M, Golda S, Ficek J, Jantas D, Przewlocki R, Korostynski M. Regulation of alternative gene transcription in the striatum in response to antidepressant drugs. Neuropharmacology. 2015.
39. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35.
40. Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561-9.
41. Yamanaka H, Yokoyama C, Mizuma H, Kurai S, Finnema SJ, Halldin C, Doi H, Onoe H. A possible mechanism of the nucleus accumbens and ventral pallidum 5-HT1B receptors underlying the antidepressant action of ketamine: a PET study with macaques. Transl Psychiatry. 2014;4:e342.
42. Gupta A, Devi LA, Gomes I. Potentiation of mu-opioid receptor-mediated signaling by ketamine. J Neurochem. 2011;119(2):294-302.
43. Piechota M, Korostynski M, Solecki W, Gieryk A, Slezak M, Bilecki W, Ziolkowska B, Kostrzewa E, Cymerman I, Swiech L, et al. The dissection of transcriptional modules regulated by various drugs of abuse in the mouse striatum. Genome Biol. 2010;11(5):R48.
44. Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, Carlezon Jr WA. Effects of striatal DeltaFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry. 2014;76(7):550-8.
45. Kos T, Popik P. A comparison of the predictive therapeutic and undesired side-effects of the NMDA receptor antagonist, memantine, in mice. Behav Pharmacol. 2005;16(3):155-61.
46. Yamamoto H, Kamegaya E, Sawada W, Hasegawa R, Yamamoto T, Hagino Y, Takamatsu Y, Imai K, Koga H, Mishina M, et al. Involvement of the N-methyl-D-aspartate receptor GluN2D subunit in phencyclidine-induced motor impairment, gene expression, and increased Fos immunoreactivity. Mol Brain. 2013;6:56.
47. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.